Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2005-03-28
2008-05-06
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S232100, C424S204100, C435S069100
Reexamination Certificate
active
07368116
ABSTRACT:
The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5126132 (1992-06-01), Rosenberg
patent: 5206353 (1993-04-01), Berger et al.
patent: 5738852 (1998-04-01), Robinson et al.
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 7211432 (2007-05-01), Schlom et al.
patent: WO 91 02805 (1991-03-01), None
patent: WO 92 19266 (1992-11-01), None
patent: WO 92 20356 (1992-11-01), None
patent: WO 94/16716 (1994-08-01), None
patent: WO 94/24267 (1994-10-01), None
Balloul et al., Recombinant Muc 1 Vaccinia Virus: A Potential Vector for Immunotherapy of Breast Cancer, Cellular and Molecular Biology, 40 (Suppl.) 49-59, 1994.
Ramsay et al., Enhancement of Mucosal IgA Responses by Interleukins 5 and 6 Encoded in Recombinant Vaccine Vectors, Reprod. Fertil. Dev., 1994, 6, 389-92.
Expression of Proteins in Mammalian Cells Using Vaccinia Viral Vectors, Overview of the Vaccinia Virus Expression System,Current Protocols in Molecular Biology,Section IV, Unit 16.15 to 16.19.9, 1991.
Schwartz, Costimulation of T Lymphocytes: The Role of CE28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy,Cell,vol. 71, 1065-1068, Dec. 24, 1992.
Chen et al., Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4,Cell,vol. 71, 1093-1102, Dec. 24, 1992.
Hellstrom et al., On the Role of Costimulation in Tumor Immunity,Annals of the New York Academy of Sciences,vol. 690, pp. 225-231, Aug. 12,1993.
Kantor et al., Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine,Journal of the National Cancer Institute,Jul. 15, 1992, vol. 84, No. 14, pp. 1084-1091.
Freeman et al., B7. A New Member of the Ig Superfamily With Unique Expression on Activated and Neoplastic B Cells,The Journal of Immunology,vol. 143, No. 8, Oct. 15, 1989, pp. 2714-2722.
Freeman et al., Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7,J. Exp. Med.,vol. 174, Sep. 1991, pp. 625-631.
Freeman et al., Uncovering of Functional Alternative CTLA-4 Counter Receptor in B7-Deficient Mice,Science,vol. 262, Nov. 5, 1993, pp. 907-909.
Freeman et al., Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation,Science,vol. 262, Nov. 5, 1993, pp. 909-911.
Schlom, J. et al., Recombinant Vaccines for the Active Specific Immunotherapy of Human Cancer, Human Cancer,AIDS Research and Human Retroviruses,vol. 10, Supplement 1, Aug. 1994, Abstract.
Hathcock et al, Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function,The Journal of Experimental Medicine,vol. 180, Aug. 1994, pp. 631-640.
Kaufman et al, A Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (CEA),Int. J. Cancer,48, pp. 900-907, 1991.
Current Protocols in Molecular Biology,Generation of Recombinant Vaccinia Viruses, vol. 2 (1994), 16.17.1-16.17.16.
Chen et al, Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-Mediated Tumor Immunity,J. Exp. Med.,vol. 179, Feb. 1994, pp. 523-532.
Döhring et al, T-Helper- and Accessory-Cell-Independent Cytotoxic Responses to Human Tumor Cells Transfected With a B7 Retroviral Vector, Int. J. Cancer, vol. 57, pp. 754-759, 1994.
Li et al, Costimulation of Tumor-Reactive CD4+ and CD8+ T Lymphocytes by B7, A Natural Ligand for CD28, Can Be Used to Treat Established Mouse Melanoma,The Journal of Immunology,vol. 153, No. 1, Jul. 1, 1994, pp. 421-428.
Bei et al, Enhanced Immune Responses and Anti-Tumor Activity by Baculovirus Recombinant Carcinoembryonic Antigen (CEA) in Mice Primed With the Recombinant Vaccinia CEA,Journal of Immunotherapy,vol. 16, No. 4, 1994, pp. 275-282.
Hodge et al, Induction of Antitumor Immunity by Recombinant Vaccinia Viruses Expressing B7-1 or B7-2 Costimulatory Molecules,Cancer Research,vol. 54, No. 21, Nov. 1, 1994, pp. 5552-5555.
Bei et al, Serological and Biochemical Characterization of Recombinant Baculovirus Carcinoembryonic Antigen,Molecular Immunology,vol. 31, No. 10, Jul. 1994, pp. 771-780.
Azuma et al, B7 Antigen is a Second Ligand for CTLA-4 and CD28,Nature,vol. 366, pp. 76-79, Nov. 4, 1993.
Cochran et al, In Vitro Mutagenesis of the Promoter Region for a Vaccinia Virus Gene: Evidence for Tandem Early and Late Regulatory Signals,Journal of Virology,vol. 54, (No. 1) Apr. 1985, pp. 30-37.
Flexner et al., Expression of Human Interleukin-2 by Live Recombinant Virus,Vaccines,87, pp. 380-383, 1987.
Smith et al, Vaccinia Virus Expression Vectors: Construction Properties and Applications,Biotechniques,Nov./Dec. 1994, pp. 306-312.
Taniguchi et al, Structure and Expression of a Cloned cDNA for Human Interleukin-2,Nature,vol. 302, Mar. 1983, pp. 305-310.
Kawakami et al, Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor,Proc. Natl. Acad. Sci.,vol. 91, pp. 3515-3519, Apr. 1994.
Kawakami et al, Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocites Associated With in Vivo Tumor Rejection, Proc. Natl. Acad. Sci., vol. 91, pp. 6458-6462, Jul. 1994.
Kawakami et al, Identification of the Immunodominant Peptides of the Mart-1 Human Melanoma Antigen Recognized by the Majority of HLA-12-Restricted Tumor Infiltrating Lymphocytes,The Journal of Experimental Medicine,vol. 180, Jul. 1994, pp. 347-352.
Brichard et al, The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,J. Exp. Med.,vol. 178, Aug. 1993, pp. 489-495.
Townsend et al, Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells,Science,vol. 259, Jan. 15, 1993, pp. 368-370.
June et al, The B7 and CD28 Receptor Families,Immunology Today,vol. 15, No. 7, 1994, pp. 321-331.
Rosenberg et al, Treatment of 283 Consecutive Patients with Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2,Jama, vol. 271, No. 12, Mar. 23/30, 1994, pp. 907-913.
Rosenberg et al, Experience With the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients,Annals of Surgery,vol. 210, No. 4, Oct. 1989, pp. 474-485.
Ochalek et al, In Vitro Generation of Therapeutic Noncytolytic T-Cells by Soluble Polyoma TAA and II-2,Anticancer Res.,Jul.-Aug. 1993, 13(4):1171-7.
Hazama et al, Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein P by Fusion With Biologically Active Interleuhin-2,Vaccine1993; 11(6):629-36.
Hinuma et al, A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen,FEBS Letters,1991, vol. 288, No. 1, 2, pp. 138-142.
Karupiah et al, Recombinant Vaccine Vector-Induced Protection of Athymic, Nude Mice From Influenza A Virus Infection. Analysis of Protective Mechanisms,Scand J Immunol.Jul. 1992;36(1):99-105.
Chen et al, Costimulation of T Cells for Tumor Immunity,Immunology Today,vol. 14, No. 10, 1993, pp. 483-486.
Gaugler et al, Human Gene Mage-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes, J. Exp. Med. vol. 179, Mar. 1994, pp. 921-930.
Freeman et al, B7.1 A New Member of the IG Superfamily With Unique Expression on Activated and Neoplastic B Cells,J. Immunol.,vol. 143, 1989, pp. 2714-2722.
Townsend et al, Tumor Rejection After Direct Costimulation of CDB+ T Cells by B7-Transfected Melanoma Cells,Science,vol. 259, 1993, pp. 368-370.
Anichina et al, Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2-Restricted Cytotoxic T Cells Clones From Melanoma Patie
Hodge James W.
Kantor Judith
Schlom Jeffrey
Leydig , Voit & Mayer, Ltd.
Salimi Ali R.
The United States of America as represented by the Department of
LandOfFree
Method of enhancing a targeted immune response against tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of enhancing a targeted immune response against tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing a targeted immune response against tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986806